Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 13/20 | 0.65 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.45 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1158385 | 0.88 | ZAP70 (0.68) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1158001 | 0.86 | ZAP70 (0.64) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1047997 | 0.86 | ZAP70 (0.73) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL12874284 | 0.85 | ZAP70 (0.65) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1158457 | 0.85 | ZAP70 (0.67) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1158266 | 0.85 | ZAP70 (0.64) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1158422 | 0.85 | ZAP70 (0.64) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1158316 | 0.82 | ZAP70 (0.69) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1158315 | 0.82 | ZAP70 (0.61) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 | |
| SCHEMBL1046926 | 0.82 | ZAP70 (0.69) | ZAP70MAPKAPK5JAK2TTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | claimed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2011014515-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | ZAP70 5/4885MAPKAPK5 407/4885JAK2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.